Press Room

News / Aug 09, 2021

Our knowledge is available 365 days for you

Summer series

Knowledge 365 our experts content always available | Hovione

Our knowledge is available 365 days for you.

Count on our multidisciplinary teams to exchange knowledge, ideas, and experience to develop and improve your project. As a specialist integrated CDMO we are dedicated to helping you bring new and off-patent drugs to market faster.

Challenge us

 

Our scientists attend the leading events of the pharma industry throughout the year where they share their knowledge and present their innovative work.

 

Did you miss the articles on Pharmaceutical Technology, Drug Development & Delivery, On-Drug Delivery or Chemistry Today? You are still in time to read them. Access them here: 

 

pharmatech logo | Hovione

 

Drug Development and Delivery Logo | Hovione

 



Moving Beyond

Particle Size Control




Contributors:

João Henriques (Group Leader,

R&D Drug Product Development)

Mafalda Paiva (Group Leader, Analytical Development)


 


Improving Bioavailability

& Solubility: Each Molecule

Is Unique - Emerging Platforms

Address Extreme Compounds




Contributor: João Henriques

(Group Leader, R&D

Drug Product Development)


 
ondrugdelivery logo | Hovione

 

chemistry today chimica oggi logo | Hovione

 



Semi-Automation in

Inhaler Testing - Exploring

the Potential & Practicalities




Discussion with João Pereira

(Team Leader, R&D Analytical Development)

Raquel Borda d' Água

(Associate Analytical Chemist, R&D Analytical Development; Copley) 


 


Where Continuous Flow

can help in today’s

Pharmaceutical Industry




Panel Discussion with

Rudi Oliveira

(Scientist, R&D Process

Engineering and Scale-up)









































 

 

 

 

 

 

 

Did you miss our presentations at DDF, RDD, DDL or AIChE?

You are still in time to join. Access them here:

 

 

ddf summit 2021 logo | Hovione

 

rdd 2021 logo | Hovione

 



Technology & Innovation



Performance Enhancement Strategies for

Low Solubility APIs – do more with less




Authors: Mafalda Paiva &

João Henriques

 



Workshop Presentation



Fully Integrated

DPI Development

From API To Device




Authors: João Pereira,

Beatriz Noriega Fernandes

aiche 2020 logo | Hovione

 

ddl 2020 logo | Hovione

 



Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals



Reaction Kinetic Model

Application to Speed up Development




Author: Filipe Ataíde

 



Presentation

and Paper



Spray-dried composite

formulation for lung

sustained release




Author: Beatriz Noriega Fernandes

















































































 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026